Nina Paleologos to Humans
This is a "connection" page, showing publications Nina Paleologos has written about Humans.
Connection Strength
0.143
-
Chemotherapy for low-grade gliomas. Expert Rev Neurother. 2005 Nov; 5(6 Suppl):S21-4.
Score: 0.009
-
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol. 2020 10 14; 22(10):1505-1515.
Score: 0.006
-
La Crosse encephalitis presenting like herpes simplex encephalitis in an immunocompromised adult. Clin Infect Dis. 2000 Oct; 31(4):1113-4.
Score: 0.006
-
Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology. 1999 Sep 22; 53(5):1141-3.
Score: 0.006
-
Treatment of oligodendroglioma: an update. Neuro Oncol. 1999 Jan; 1(1):61-8.
Score: 0.006
-
Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry. CNS Oncol. 2018 04; 7(2):CNS08.
Score: 0.005
-
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro Oncol. 2017 Oct 01; 19(10):1380-1390.
Score: 0.005
-
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol. 2016 Jan; 126(1):185-192.
Score: 0.005
-
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun; 17(6):854-61.
Score: 0.004
-
External beam radiotherapy: hard facts and painful realities. J Neurooncol. 1995; 24(1):93-5.
Score: 0.004
-
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2014 Nov; 16(11):1541-6.
Score: 0.004
-
Intravenous thrombolysis for ischemic stroke in recurrent oligodendroglioma: a case report. J Stroke Cerebrovasc Dis. 2014 May-Jun; 23(5):1235-8.
Score: 0.004
-
Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012 Jun; 14(6):761-7.
Score: 0.004
-
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012 07; 108(3):491-8.
Score: 0.004
-
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun; 13(6):649-59.
Score: 0.003
-
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jun; 13(6):660-8.
Score: 0.003
-
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010; 15(12):1329-34.
Score: 0.003
-
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jan; 13(1):143-51.
Score: 0.003
-
The role of the blood-brain barrier in movement disorders. Clin Neuropharmacol. 1990 Apr; 13(2):129-46.
Score: 0.003
-
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):45-68.
Score: 0.003
-
The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):71-83.
Score: 0.003
-
The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):33-43.
Score: 0.003
-
The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):17-32.
Score: 0.003
-
The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol. 2010 Jan; 96(1):115-42.
Score: 0.003
-
The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):103-14.
Score: 0.003
-
The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):97-102.
Score: 0.003
-
The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):85-96.
Score: 0.003
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 01; 27(28):4733-40.
Score: 0.003
-
Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol. 2009 Mar; 92(1):57-63.
Score: 0.003
-
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol. 2008 Sep; 89(2):187-93.
Score: 0.003
-
Growth rate of non-operated meningiomas. J Neurol. 2008 Jun; 255(6):891-5.
Score: 0.003
-
Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol. 2007 Jul; 9(3):314-8.
Score: 0.002
-
Behavioral indicators of hallucinosis in levodopa-treated Parkinson's disease. Adv Neurol. 1987; 45:417-20.
Score: 0.002
-
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol. 2006 Apr; 8(2):183-8.
Score: 0.002
-
Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists. Clin Neuropharmacol. 1986; 9(3):298-302.
Score: 0.002
-
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15; 21(22):4151-6.
Score: 0.002
-
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neurooncol. 2003 Nov; 65(2):127-34.
Score: 0.002
-
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro Oncol. 2000 04; 2(2):114-9.
Score: 0.002
-
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998 Jun; 16(6):2202-12.
Score: 0.001
-
Salvage chemotherapy for oligodendroglioma. J Neurosurg. 1996 Oct; 85(4):597-601.
Score: 0.001
-
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res. 1996 Jun; 2(6):963-72.
Score: 0.001
-
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. Int J Radiat Oncol Biol Phys. 1996 Mar 01; 34(4):793-802.
Score: 0.001
-
Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol. 1990 Dec; 28(6):818-22.
Score: 0.001